APPROPRIATE EMPIRICAL MANAGEMENT OF MICROBIAL INFECTIONS IN A TERTIARY CARE HOSPITAL: A COST- EFFECTIVENESS APPROACH.
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i2.22441Keywords:
Antibiotics, Cost-effectiveness analysis, Empirical therapy, Infection, Microorganisms, Sensitivity patternAbstract
 Objective: Antibiotics are mostly prescribed empirically to decrease health-care costs. This has led to the misuse of antibiotics thereby making them inefficient in the treatment of infections. The aim of this study was to determine the appropriate, cost-effective drug for the empirical therapy in microbial infections.
Methods: A prospective observational study was conducted for a period of 6 months. Cost-effectiveness ratio (CER) of these antibiotics prescribed was calculated to determine the cost-effective drugs for the common microorganisms and common infections.
Results: In a population of 205 patients, 54.6% were treated based on antibiotic sensitivity pattern whereas 45.3% were treated empirically. In known microbial infections, the prevailing microorganism was extended-spectrum beta-lactamase (ESBL) producing Escherichia-coli (14.3%), Staphylococcus aureus (10.6%), Pseudomonas aeruginosa (9.8%), Klebsiella pneumonia (9.8%), and K. pneumoniae ESBL (6.81%). Based on the CER, the most cost-effective drugs for these organisms were found to be ciprofloxacin, clindamycin, ofloxacin, levofloxacin, and amikacin, respectively. In unknown microbial infection (empirical treatment), Diabetic Foot Infection (DFT) (25.8%), respiratory tract infection (RTI) (23.6%), and urinary tract infection (UTI) (16.1%) were the most common infections. The most cost-effective drugs for these infections were clindamycin, levofloxacin, and azithromycin, respectively. The predominant microorganism in DFT was found to be S. aureus (71%), in UTI was found to be E. coli ESBL (52%), and in RTI were found to be P. aeruginosa (42.4%) and K. pneumonia (32.3%).
Conclusion: Appropriate empirical antibiotic treatment is associated with a lower medical cost and a better success rate in patients with microbial infections.
Downloads
References
Little P, Watson L, Morgan S, Williamson I. Antibiotic prescribing and admissions with major suppurative complications of respiratory tract infections: A data linkage study. Br J Gen Pract 2002;52:187-90.
Feldman C. Appropriate management of lower respiratory tract infections in primary care. Prim Care Respir J 2004;13:159-66.
Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000;101:2916-21.
Chow I, Lemos EV, Marr P, Machado M, Einarson TR. Pharmacoeconomic analysis of guidelines for treating mild diabetic foot infections: A decision-tree model for Canada. Can J Hosp Pharm 2008;61:412-21.
National Institute of Allergy and Infectious disease (NIAID). National Institute of Allergy and Infectious Diseases; 2013. Available from: http://www.niaid,nih.gov/topics/antimicrobialresistance/Pages/default.aspx.
Suleiman I, Bamiro SB, Mendie UE. Cost-effectiveness of six drugs for the treatment of Pseudomonas aeruginosa infections in Nigeria. Int J Pharm Pharm Sci 2014;6:239-44.
Kerr JR, Barr JG, Smyth ET, O’Hare J, Bell PM, Callender ME, et al. Antibiotic pharmacoeconomics: An attempt to find the real cost of hospital antibiotic prescribing. Ulster Med J 1993;62:50-7.
Sedighi I, Solgi A, Amanati A, Alikhani MY. Choosing the correct empirical antibiotic for urinary tract infection in pediatric: Surveillance of antimicrobial susceptibility pattern of Escherichia coli by E-test method. Iran J Microbiol 2014;6:387-91.
Thomas B, Mathew L, Jose J, Rathinavelu M. Assessment of antibiotic sensitivity pattern of microorganisms and their cost-effectiveness in private cooperative hospital. Asian J Pharm Clin Res 2004;7:155-9.
Salvatore DJ, Beth H. Resman-targoff. treatment options for urinary tract infections caused by extended-spectrum Î’-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Am J Hosp Pharm 2015;7:53-6.
Rayner C, Munckhof WJ. Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Int Med J 2005;3:3-16.
Radji M, Putri CS, Fauziyah S. Antibiotic therapy for diabetic foot infections in a tertiary care hospital in Jakarta, Indonesia. Europe PMC 2014;8:221-4.
de Vries MG, Ekkelenkamp MB, Peters EJ. Are clindamycin and ciprofloxacin appropriate for the empirical treatment of diabetic foot infections? Eur J Clin Microbiol Infect Dis 2014;33:453-6.
Harwan WA, Abbassi MM, May M. Pharmacoeconomic study of antibiotics used in the treatment of lower respiratory tract infections in ICU patients: A case study in an Egyptian hospital. Bull Fac Pharm Cairo Univ 2014;5:135-44.
Egbe CA, Ndiokwere C, Omoregie R. Microbiology of lower respiratory tract infections in Benin City, Nigeria. Malays J Med Sci 2011;18:27-31.
Dudas V, Sarah B, Trivedi KT. Implementation of an antimicrobial stewardship program targeting resistance with UTI in three community long-term care facilities: A quasi-experimental study using time-series analysis. Antimicrob Resist Infect Control 2015;4:2-8.
Bouza JM, Sangrador C, Mendez CP. The etiology of urinary tract infections and the antimicrobial susceptibility of urinary pathogens. Rev Esp Quimioter 2005;8:124-35.
Yüksel S, Oztürk B, Kavaz A. Antibiotic resistance of urinary tract pathogens and evaluation of empirical treatment in Turkish children with urinary tract infections. Int J Antimicrob Agents 2006;28:413-6.
Bisht R, Aatiyar A, Singh R, Mittal P. Antibiotic resistance - A global issue of concern. Asian J Pharm Clin Res 2009;2:34-7.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
